61587-85-7

Basic information

• Product Name: Carbamic acid, [1-(1H-indol-3-ylmethyl)-2-[[(4-methylphenyl)sulfonyl]oxy]ethyl]-, phenylmethyl ester, (S)-
• CAS NO: 61587-85-7
• Molecular Formula: C26H26N2O5S
• Molecular Weight: 478.569
• Mol File: 61587-85-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [1-(1H-indol-3-ylmethyl)-2-[[(4-methylphenyl)sulfonyl]oxy]ethyl]-, phenylmethyl ester, (S)-(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [1-(1H-indol-3-ylmethyl)-2-[[(4-methylphenyl)sulfonyl]oxy]ethyl]-, phenylmethyl ester, (S)-(61587-85-7)
• EPA Substance Registry System: Carbamic acid, [1-(1H-indol-3-ylmethyl)-2-[[(4-methylphenyl)sulfonyl]oxy]ethyl]-, phenylmethyl ester, (S)-(61587-85-7)

Safety Data

• Hazardous Substances Data: 61587-85-7(Hazardous Substances Data)

Upstream product

• 2717-76-2 (S)-N-benzyloxycarbonyl-L-tryptophan methyl ester 
• 154-09-6 L-tryptophanol 
• 73-22-3 L-Tryptophan 
• 61535-47-5 benzyl (S)-(1-hydroxy-3-(1H-indol-3-yl)propan-2-yl)carbamate 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 1192024-79-5 (S)-benzyl 1-azido-3-(1H-indol-3-yl)propan-2-ylcarbamate 
• 7795-52-0 (-)-alpha-Methyltryptamine 
• 1379661-52-5 C₂₄H₂₉N₃O₂ 
• 1379661-53-6 (S)-1-(1-(1H-indol-3-yl)-3-(piperidin-1-yl)propan-2-yl)-3-(3,5-bis(trifluoromethyl)phenyl)thiourea 

Relevant articles and documents

ESTROGEN RECEPTOR MODULATORS

Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.

Spirotetrahydro β-carbolines (spiroindolones): A new class of potent and orally efficacious compounds for the treatment of malaria

The antiplasmodial activity of a series of spirotetrahydro β-carbolines is described. Racemic spiroazepineindole (1) was identified from a phenotypic screen on wild type Plasmodium falciparum with an in vitro IC50 of 90 nM. Structure-activity relationships for the optimization of 1 to compound 20a (IC50 = 0.2 nM) including the identification of the active 1R,3S enantiomer and elimination of metabolic liabilities is presented. Improvement of the pharmacokinetic profile of the series translated to exceptional oral efficacy in the P. berghei infected malaria mouse model where full cure was achieved in four of five mice with three daily doses of 30 mg/kg.